Sidra introduces two therapies for childhood neuroblastoma
Sidra Medicine says it has administered naxitamab for the first time in the Gulf Cooperation Council region and dinutuximab beta for the first time in Qatar to treat high-risk neuroblastoma. Both are anti-GD2 monoclonal antibody therapies.
Sidra Medicine announced on 30 September that it had introduced two specialised therapies for children with high-risk neuroblastoma: naxitamab (Danyelza), for the first time in the GCC, and dinutuximab beta (Qarziba), for the first time in Qatar. The hospital said both medicines are anti-GD2 monoclonal antibody therapies.
The treatments were administered to two patients after stem-cell transplantation. Sidra said the work involved coordination between its paediatric haematology and oncology and haematopoietic stem-cell transplant teams, adding to the specialised options available at the hospital for high-risk neuroblastoma.
MSF and Epicentre launched BRAVO on 19 September to study the use of ERVEBO among 20,000 frontline workers in Ituri and North Kivu; the study will include vaccination and follow-up.
Hamad Medical Corporation says it has performed Qatar’s first subperiosteal jaw implant and reconstruction using three-dimensional imaging and virtual surgical planning. The procedure used custom components for a patient who was not suited to conventional implants.
A new clinic at Hamad General Hospital brings pulmonary and sleep medicine together with psychiatry to assess and treat non-respiratory sleep disorders in adults. Home sleep studies and overnight polysomnography may be used when needed.
Google Analytics can measure visits and site activity using cookies if you allow it. You can change your choice later.
Measurement and privacy details
Google Analytics measurement starts only if you allow it. After consent, automatic measurement may cover scrolls, outbound link clicks, downloads, video engagement, site searches and basic form interactions; search terms may be detected from URL parameters. This site’s own code does not send form field values; email redaction in automatic measurement is best-effort, not guaranteed. Our manual page-view event uses a cleaned URL. You can change your choice later. Visits that begin with consent may also send numeric LCP, INP and CLS performance measurements after Analytics loads. A first or later grant starts this on the next page load; withdrawing consent stops these performance reports for this page. The preference cookie lasts six months; advertising measurement and personalization stay off.
Your browser is sending a Global Privacy Control signal. Analytics is off by default; you may explicitly change this choice here.
